Business Context and Reporting Period
This Form 8-K filing by Biorestorative Therapies, Inc. covers events occurring between September 10, 2019, and October 2, 2019, with a report date of September 30, 2019. The company is an emerging growth company incorporated in Delaware. The filing primarily addresses unregistered sales of equity securities and the issuance of convertible debt.
Key Financial Metrics and Capital Structure
- Debt-for-Equity Exchange: The company issued 1,332,375 shares of common stock to settle outstanding indebtedness totaling $155,467 (including accrued interest).
- Convertible Note Issuance: The company issued convertible promissory notes with an aggregate principal amount of $423,750.
- Cash Proceeds: The issuance of the convertible notes generated aggregate cash proceeds of $375,655.
- Interest Rates: The new notes bear interest at rates ranging from 10% to 12% per annum.
- Maturity Dates: Original maturity dates for the notes range from June 2020 to September 2020.
Material Changes and Transaction Details
The filing details significant changes to the company's capital structure through two primary mechanisms:
- Debt Reduction: A reduction in outstanding debt of $155,467 was achieved through the conversion of debt into equity.
- New Financing: The company secured new financing via convertible notes. The conversion terms vary by tranche:
- $183,750 principal convertible at a fixed price of $1.00 per share for the first six months, then at 58% of fair value.
- $90,000 principal convertible after 180 days at 58% of fair value.
- $150,000 principal convertible after 180 days at the lower of the closing price preceding issuance or 58% of fair value.
The filing text does not provide specific values for revenue, operating profit, cash flow from operations, or overall liquidity ratios for the period.
Guidance, Risks, and Unusual Items
Regulatory Compliance: The company relied on Section 4(a)(2) and Section 3(a)(9) of the Securities Act of 1933 for these transactions, asserting they were not public offerings and were made to accredited investors without general solicitation.
Risks and Contingencies: The filing does not explicitly list new risk factors or contingencies beyond the standard terms of the convertible notes. However, the dilutive nature of the conversion features (specifically the 58% discount to fair value) represents a potential future dilution risk for existing shareholders.
Management Commentary: No forward-looking guidance regarding revenue or operational milestones is provided in this specific filing.
Investor Verification Checklist
- Verify the total number of shares outstanding post-issuance to assess dilution impact.
- Confirm the current fair market value of the stock to evaluate the potential conversion price of the $423,750 in notes.
- Review the company's cash balance to determine if the $375,655 in proceeds is sufficient to meet operational needs until the note maturities in mid-to-late 2020.
- Check subsequent filings for any early conversions of the notes or additional debt issuances.